Boston Scientific Corp. BSX
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Boston Scientific Corp. (BSX) Core Market Data and Business Metrics
Latest Closing Price
$100.05Price-Earnings Ratio
80.04Total Outstanding Shares
1.48 Billion SharesDividend
No dividendSIC Description
Surgical & Medical Instruments & ApparatusPrimary Exchange
New York Stock ExchangeHeadquarters
300 Boston Scientific Way, Marlborough, MA, 01752-1234
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 9,484,266 Shares | 1.33 | 3/14/2025 | 12,623,573 Shares |
| 8,036,802 Shares | 1.6 | 2/28/2025 | 12,873,554 Shares |
| 6,498,679 Shares | 1.76 | 2/14/2025 | 11,456,307 Shares |
| 6,328,021 Shares | 1.65 | 1/31/2025 | 10,449,826 Shares |
| 5,362,048 Shares | 2.69 | 1/15/2025 | 14,397,966 Shares |
| 5,104,130 Shares | 2.85 | 12/31/2024 | 14,523,331 Shares |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities | $1.81 Billion |
| Net Cash Flow From Operating Activities | $3.44 Billion |
| Net Cash Flow From Investing Activities, Continuing | $-5.69 Billion |
| Net Cash Flow From Financing Activities, Continuing | $1.81 Billion |
| Net Cash Flow, Continuing | $-438 Million |
| Net Cash Flow | $-449 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Revenues | $16.75 Billion |
| Operating Expenses | $8.89 Billion |
| Costs And Expenses | $14.46 Billion |
| Income Tax Expense/Benefit | $436 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Cost Of Revenue | $5.26 Billion |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $2.06 Billion |
| Comprehensive Income/Loss Attributable To Parent | $2.08 Billion |
| Other Comprehensive Income/Loss | $218 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $-15 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Equity Attributable To Noncontrolling Interest | $233 Million |
| Accounts Payable | $960 Million |
| Current Liabilities | $6.40 Billion |
| Fixed Assets | $3.29 Billion |
| Assets | $39.40 Billion |
| Inventory | $2.81 Billion |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||